All In Biotech

Drug Trial Radar · NCT05239143

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Feb 15, 2022

Primary completion

Apr 2039

Study completion Apr 2039

Sponsor

Lead sponsor
Poseida Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.

Conditions

  • Breast Cancer
  • Ovarian Cancer
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Renal Cell Carcinoma
  • Nasopharyngeal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Gastric Cancer

Interventions

  • P-MUC1C-ALLO1 CAR-T cellsBiological

    P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

  • RimiducidDrug

    Rimiducid (safety switch activator) may be administered as indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1Time frame: Baseline through Day 28
  2. Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1Time frame: Baseline through 15 years
  3. Evaluate the preliminary efficacy of P-MUC1C-ALLO1Time frame: Baseline through 15 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine Medical Center

    Irvine, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California, San Diego

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • University of Maryland Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Montefiore Medical Center

    The Bronx, New York

  • MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.